Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy

European Journal of Immunology

Volumn 40, Issue 9, 2010, Pages 2569-2579

  Wang, Lixin ^a,b   Liu, Jin Qing ^a   Talebian, Fatemeh ^a   El Omrani, Hani Y ^a   Khattabi, Mazin ^a   Yu, Li ^b   Bai, Xue Feng ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CD200; CTL; Immune evasion; Tumor associated myeloid cells

Indexed keywords

ANTIGENS, CD200; CANCER VACCINE; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; CANCER TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; DBA MOUSE; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; MASTOCYTOMA; METABOLISM; MOUSE; PATHOLOGY; PLASMACYTOMA; SECRETION (PROCESS); TRANSGENE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; GRAFT VS TUMOR EFFECT; INTERLEUKIN-10; MASTOCYTOMA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES; TUMOR ESCAPE;

EID: 77956471050     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040472     Document Type: Article

References (44)

1. Preston, S., Wright, G. J., Starr, K., Barclay, A. N. and Brown, M. H., The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages. Eur. J. Immunol. 1997. 27: 1911-1918.
2. McWhirter, J. R., Kretz-Rommel, A., Saven, A., Maruyama, T., Potter, K. N., Mockridge, C. I., Ravey, E. P. et al., Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. USA 2006. 103: 1041-1046.
3. Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P. et al., CD200 is a new prognostic factor in multiple myeloma. Blood 2006. 108: 4194-4197.
4. Tonks, A., Hills, R., White, P., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L., CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007. 21: 566-568.
5. Siva, A., Xin, H., Qin, F., Oltean, D., Bowdish, K. S. and Kretz-Rommel, A., Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother. 2008. 57: 987-996.
6. Petermann, K. B., Rozenberg, G. I., Zedek, D., Groben, P., McKinnon, K., Buehler, C., Kim, W. Y. et al., CD200 is induced by ERK and is a potential therapeutic target in melanoma. J. Clin. Invest. 2007. 117: 3922-3929.
7. Wright, G. J., Cherwinski, H., Foster-Cuevas, M., Brooke, G., Puklavec, M. J., Bigler, M., Song, Y. et al., Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 2003. 171: 3034-3046. (Pubitemid 37093527)
8. Jenmalm, M. C., Cherwinski, H., Bowman, E. P., Phillips, J. H. and Sedgwick, J. D., Regulation of myeloid cell function through the CD200 receptor. J. Immunol. 2006. 176: 191-199.
9. Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B. et al., Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000. 290: 1768-1771. (Pubitemid 32004808)
10. Snelgrove, R. J., Goulding, J., Didierlaurent, A. M., Lyonga, D., Vekaria, S., Edwards, L., Gwyer, E. et al., A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 2008. 9: 1074-1083.
11. Gorczynski, R. M., Chen, Z., Hu, J., Kai, Y. and Lei, J., Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin. Exp. Immunol. 2001. 126: 220-229.
12. Kretz-Rommel, A., Qin, F., Dakappagari, N., Ravey, E. P., McWhirter, J., Oltean, D., Frederickson, S. et al., CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 2007. 178: 5595-5605.
13. Kretz-Rommel, A., Qin, F., Dakappagari, N., Cofiell, R., Faas, S. J. and Bowdish, K. S., Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J. Immunol. 2008. 180: 699-705.
14. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E. and Boon, T., The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 1991. 173: 1373-1384.
15. Ramarathinam, L., Sarma, S., Maric, M., Zhao, M., Yang, G., Chen, L. and Liu, Y., Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 1995. 155: 5323-5329.
16. Lethe, B., van den Eynde, B., van Pel, A., Corradin, G. and Boon, T., Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 1992. 22: 2283-2288.
17. Sarma, S., Guo, Y., Guilloux, Y., Lee, C., Bai, X. F. and Liu, Y., Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J. Exp. Med. 1999. 189: 811-820.
18. Bai, X. F., Bender, J., Liu, J., Zhang, H., Wang, Y., Li, O., Du, P. et al., Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol. 2001. 167: 3936-3943. (Pubitemid 32910839)
19. Bai, X. F., Gao, J. X., Liu, J., Wen, J., Zheng, P. and Liu, Y., On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res. 2001. 61: 6860-6867. (Pubitemid 32896511)
20. Bai, X. F., Liu, J., May Jr, K. F., Guo, Y., Zheng, P. and Liu, Y., B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 2002. 99: 2880-2889. (Pubitemid 34525377)
21. Bai, X. F., Liu, J., Li, O., Zheng, P. and Liu, Y., Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest. 2003. 111: 1487-1496.
22. Bai, X. F., Liu, J. Q., Joshi, P. S., Wang, L., Yin, L., Labanowska, J., Heerema, N. et al., Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res. 2006. 66: 8241-8249. (Pubitemid 44299193)
23. Minas, K. and Liversidge, J., Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 2006. 26: 213-230.
24. Kim, R., Emi, M., Tanabe, K. and Arihiro, K., Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006. 66: 5527-5536.
25. Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S., Kimura, Y. N., Hamano, S., Sonoda, K. H. et al., Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J. Clin. Invest. 2005. 115: 2979-2991.
26. Lewis, C. E. and Pollard, J. W., Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006. 66: 605-612.
27. Bronte, V. and Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005. 5: 641-654.
28. Barclay, A. N., Wright, G. J., Brooke, G. and Brown, M. H., CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002. 23: 285-290.
29. Zhang, S., Cherwinski, H., Sedgwick, J. D. and Phillips, J. H., Molecular mechanisms of CD200 inhibition of mast cell activation. J. Immunol. 2004. 173: 6786-6793.
30. Copland, D. A., Calder, C. J., Raveney, B. J., Nicholson, L. B., Phillips, J., Cherwinski, H., Jenmalm, M. et al., Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am. J. Pathol. 2007. 171: 580-588.
31. Greifenberg, V., Ribechini, E., Rossner, S. and Lutz, M. B., Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009. 39: 2865-2876.
32. Gabrilovich, D. I. and Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009. 9: 162-174.
33. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002. 23: 549-555.
34. Balkwill, F., Charles, K. A. and Mantovani, A., Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005. 7: 211-217.
35. Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. and Ostrand- Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007. 179: 977-983.
36. Spiotto, M. T., Rowley, D. A. and Schreiber, H., Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004. 10: 294-298.
37. Spiotto, M. T. and Schreiber, H., Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 2005. 5: 8.
38. Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P. et al., Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 2007. 204: 49-55.
39. Zhang, B., Karrison, T., Rowley, D. A. and Schreiber, H., IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 2008. 118: 1398-1404.
40. Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H. and Blankenstein, T., A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003. 63: 4095-4100.
41. Lu, Y., Yang, W., Qin, C., Zhang, L., Deng, J., Liu, S. and Qin, Z., Responsiveness of stromal fibroblasts to interferon-gamma blocks tumor growth via angiostasis. J. Immunol. 2009. 183: 6413-6421.
42. Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C. and Balkwill, F. R., "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008. 205: 1261-1268.
43. Muller-Hermelink, N., Braumuller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K. et al., TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008. 13: 507-518.
44. Tomayko, M. M. and Reynolds, C. P., Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989. 24: 148-154.